Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.86 EPS, down 8.14% or $0.07 from last year’s $-0.79 per share.

At the moment 5 analysts are watching Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), 3 rate it “Buy”, 1 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 0.00 million. For the quarter ending Sep-16, 2 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 2 analysts have a mean target of 2.00 million.

In terms of earnings per share, 2 analysts have a -0.91 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 2 analysts have a -0.98 EPS mean target and for the quarter ending Sep-16 there are 3 estimates of -3.45 EPS.

The biggest institutional shareholders in Dicerna Pharmaceuticals, Inc. include Fidelity Management and Research Company which owns 3 million shares in the company valued at $36.67 million. Wellington Management Company LLP is the second biggest holder with 2 million shares currently valued at 28.86 million whilst RA Capital Management, LLC has 2 million shares valued at 28.83 million.

Total shares held by institutions as of the most recent company filings are 17,209,492 with a reported 868,614 bought and 661,269 sold. These holdings make up 83.35% of the company’s outstanding shares.

Currently insiders hold 215,861 shares in the business which makes up 1.05% of shares. The biggest holder currently is David M. Madden who owns 120,011 shares (0.58% of those outstanding), whilst Dr. Douglas M. Fambrough, III holds 19,800 (0.10% of shares outstanding) and Bob Brown holds 19,339 (0.09% of shares outstanding).

The stock decreased 4.32% or $0.18 during the last trading session, hitting $6.00. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has fallen 95.33% over the past 6 months and is downtrending.